RIPK3 and neoplasm: To further demonstrate this, we used the MLKL inhibitor Necrosulfonamide (NSA) to inhibit necroptosis and observed that overexpressed RIP3 no longer inhibited the tumor cells’ ability to proliferate (Figure 6I).